Dansk Lunge Cancer Register har leveret data til eller bidraget til følgende publikationer:


  1. Blum, T. G., Morgan, R. L., Durieux, V., Chorostowska-Wynimko, J., Baldwin, D. R., Boyd, J., Faivre-Finn, C., Galateau-Salle, F., Gamarra, F., Grigoriu, B., Hardavella, G., Hauptmann, M., Jakobsen, E., Jovanovic, D., Knaut, P., Massard, G., McPhelim, J., Meert, A-P., Milroy, R., Muhr, R., & 15 flereEuropean Respiratory Society Guideline on various aspects of quality in lung cancer care. 17. nov. 2022, (E-pub ahead of print) I: European Respiratory Journal.
  2. Langballe, R., Dalton, S. O., Jakobsen, E., Karlsen, R. V., Iachina, M., Freund, K. M., Leclair, A., Nielsen, A. S., Andersen, E. A. W., Rosthøj, S., Jørgensen, L. B., Skou, S. T. & Bidstrup, P. E., NAVIGATE: improving survival in vulnerable patients with lung cancer through nurse navigation, symptom monitoring and exercise – study protocol for a multicentre randomised controlled trial. 31. okt. 2022, I: BMJ Open. 12, 10, s. e060242
  3. Lynch, C., Harrison, S., Butler, J., Baldwin, D. R., Dawkins, P., van der Horst, J., Jakobsen, E., McAleese, J., McWilliams, A., Redmond, K., Swaminath, A. & Finley, C. J., An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership. 22. okt. 2022, I: Cancer Control. 29, 9 s.
  4. Ehrenstein, V., Eriksen, K., Taylor, A., Servidio, L. & Jakobsen, E., Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark.  20. jun. 2022, (E-pub ahead of print) I: Cancer Medicine.
  5. Stenger, M., Jakobsen, E., Wright, G., Zalcberg, J. & Stirling, R. G., A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. maj 2022, I: ANZ Journal of Surgery. 92, 5, s. 1050-1055
  6. Araghi, M., Fidler-Benaoudia, M., Arnold, M., Rutherford, M., Bardot, A., Ferlay, J., Bucher, O., De, P., Engholm, G., Gavin, A., Kozie, S., Little, A., Møller, B., St Jacques, N., Tervonen, H., Walsh, P., Woods, R., O’Connell, D. L., Baldwin, D., Elwood, M., & 5 flereInternational differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study apr. 2022, I: Thorax. 77, 4, s. 378-390


  1. Fjaellegaard K, Koefod Petersen J, Reuter S, Malene Fischer B, Gerke O, Porcel JM, Frost Clementsen P, Laursen CB, Bhatnagar R, Bodtger U. Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis. Lung Cancer. 2021 Dec;162:106-118.
  2. Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, Hansen KH, Grønberg BH, Cicenas S, Koivunen JP, Mellemgaard A, Brustugun OT. Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. Acta Oncol. 2021 Dec;60(12):1565-1571.
  3. Bodtger U, Marsaa K, Siersma V, Bang CW, Høegholm A, Brodersen J. Breaking potentially bad news of cancer workup to well-informed patients by telephone versus in-person: A randomised controlled trial on psychosocial consequences. Eur J Cancer Care (Engl). 2021 Sep;30(5):e13435
  4. Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Efficacy and Safety of Rovalpituzumab Tesirine. Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. J Thorac Oncol. 2021 Sep;16(9):1547-1558.
  5. Matzen E, Bartels LE, Løgstrup B, Horskær S, Stilling C, Donskov F. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. 2021 Aug 9;7(1):27.
  6. Abdulbaqi IM, Assi RA, Yaghmur A, Darwis Y, Mohtar N, Parumasivam T, Saqallah FG, Wahab HA. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. (Basel). 2021 Jul 27;14(8):725.
  7. Aredo JV, Luo SJ, Gardner RM, Sanyal N, Choi E, Hickey TP, Riley TL, Huang WY, Kurian AW, Leung AN, Wilkens LR, Robbins HA, Riboli E, Kaaks R, Tjønneland A, Vermeulen RCH, Panico S, Le Marchand L, Amos CI, Hung RJ, Freedman ND, Johansson M, Cheng I, Wakelee HA, Han SS. Tobacco Smoking and Risk of Second Primary Lung Cancer. J Thorac Oncol. 2021 Jun;16(6):968-979.
  8. Ehrenstein V, Huang K, Kahlert J, Bahmanyar S, Karlsson P, Löfling L, Nunes AP, Enger C, Bezemer ID, Kuiper JG, Hoti F, Juuti R, Korhonen P, Mo J, Schachterle SE, Wilner KD, Rørth M, Sørensen HT. Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):758-769.
  9. Christensen TN, Langer SW, Persson G, Larsen KR, Loft A, Amtoft AG, Berthelsen AK, Johannesen HH, Keller SH, Kjaer A, Fischer BM. 18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. J Nucl Med. 2021 May 10;62(5):628-635.
  10. Ricciardi S, Booton R, Petersen RH, Infante M, Scarci M, Veronesi G, Cardillo G. Managing of screening-detected sub-solid nodules-a European perspective. Transl Lung Cancer Res. 2021 May;10(5):2368-2377
  11. Hurtado FK, de Braud F, De Castro Carpeño J, de Miguel Luken MJ, Wang D, Scott J, Lau YY, McCulloch T, Mau-Sorensen M. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors. Cancer Chemother Pharmacol. 2021 Apr;87(4):475-486.
  12. MC, Stevens VL, Jin G, Christiani DC, Hu Z, Amos CI, Ma H, Shen H. Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma. Front Med. 2021 Apr;15(2):275-291.
  13. Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021 Mar;22(3):321-331.
  14. Krarup MMK, Krokos G, Subesinghe M, Nair A, Fischer BM. Artificial Intelligence for the Characterization of Pulmonary Nodules, Lung Tumors and Mediastinal Nodes on PET/CT. Semin Nucl Med. 2021 Mar;51(2):143-156.
  15. Franzyk H, Christensen SB. Targeting Toxins toward Tumors. 2021 Feb 27;26(5):1292.
  16. Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assunção JA, Conde L, Furness AJS, Saini SK, Hadrup SR, Herrero J, Lee SH, Van Loo P, Enver T, Larkin J, Hellmann MD, Turajlic S, Quezada SA, McGranahan N, Swanton C. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021 Feb 4;184(3):596-614.e14.
  17. Sandfeld-Paulsen B, Aggerholm-Pedersen N, Winther-Larsen A. Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2021 Feb;10(2):651-661.
  18. Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O, Høilund-Carlsen PF, Morsing A, Andersen TL. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):584-591.
  19. Tobberup R, Carus A, Rasmussen HH, Falkmer UG, Jorgensen MG, Schmidt EB, Jensen NA, Mark EB, Delekta AM, Antoniussen CS, Bøgsted M, Holst M. Feasibility of a multimodal intervention on malnutrition in patients with lung cancer during primary anti-neoplastic treatment. Clin Nutr. 2021 Feb; 40(2): 525-533.
  20. Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B. Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis. Syst Rev. 2021 Jan 28; 10(1):40.
  21. Christensen TN, Andersen PK, Langer SW, Fischer BMB. Prognostic Value of 18F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics (Basel). 2021 Jan 26;11(2):174.
  22. Bredtoft EN, Madsen HH, Rasmussen TR. Stage I lung cancer patients with or without symptoms – are the patients different and should we treat them differently? Acta Oncologica 2021 Sept; 60(9): 1169-1174.
  23. Danckert B, Falborg AZ, Christensen NL, Frederiksen H, Lyratzopoulos G, McPhail S, Ryg J, Vedsted P, Thomsen LA, Jensen H. Routes to diagnosis and the association with the prognosis in patients with cancer – A nationwide register-based cohort study in Denmark. Cancer Epidemiology 2021 Oct;74: 101983
  24. Gouliaev A, Risikesan J, Christensen NL, Rasmussen TR, Hilberg O, Ibsen R, Løkke A. Direct and indirect economic burden of lung cancer in Denmark a nationwide study. Eur Clin Respir J. 2021 Jul 29;8(1):1951963
  25. Borg M, Løkke A, Rasmussen TR. Symptoms and lung function follow-up after lung cancer resection. Dan Med J. 2021 Sep 15;68(10)
  26. Cronin-Fenton D, Dalvi T, Movva N, Pedersen L, Hansen H, Fryzek J, Hedgeman E, Mellemgaard A, Rasmussen TR, Shire N, Hamilton-Dutoit S, Nørgaard M. PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study. Sci Rep. 2021 Aug 19;11(1):16892.
  27. Samson MH, Abildgaard AM, Espelund U, Rasmussen TR, Folkersen B, Frystyk J, Nexo E. Circulating trefoil factors in relation to lung cancer, age and lung function: a cross-sectional study in patients referred for suspected lung cancer. Scand J Clin Lab Invest. 2021 Oct;81(6):446-450. pub 2021 Jul 9.
  28. Hedgeman E, Nørgaard M, Dalvi T, Pedersen L, Hansen HP, Walker J, Midha A, Shire N, Boothman AM, Fryzek JP, Rigas J, Mellemgaard A, Rasmussen TR, Hamilton-Dutoit S, Cronin-Fenton D. Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. Cancer Epidemiol. 2021 Aug; 73: 101976.
  29. Friis RB, Hjøllund NH, Pappot H, Taarnhøj GA, Vestergaard JM, Skuladottir H. Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer. Clin Lung Cancer. 2021 Mar;22(2):e169-e179.
  30. Grønberg BH, Langer SW, Nyman J, Halvorsen TO. Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer – Authors’ reply. Lancet Oncol. 2021 Jun;22(6):e222.
  31. Soldath P, Binderup T, Kjær A, Federspiel B, Langer SW, Knigge U, Petersen RH. Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer. 2021 Jun;156:109-116.
  32. Christensen TN, Langer SW, Persson G, Larsen KR, Amtoft AG, Keller SH, Kjaer A, Fischer BM. Impact of 18F-FDG-PET and 18F-FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics (Basel). 2021 Feb 11;11(2):279.
  33. Urbanska EM, Elversang J, Colville-Ebeling B, Löfgren JO, Nelveg-Kristensen KE, Szpirt WM. Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer. Clin Pract. 2021 May 14;11(2):293-302.
  34. Frank MS, Bodtger U, Gehl J, Ahlborn LB. Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment. Cancers (Basel). 2021 Dec 28;14(1):132.
  35. Fjaellegaard K, Koefod Petersen J, Andersen G, Biagini M, Bhatnagar R, Laursen CB, Clementsen PF, Bodtger U. The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. Eur Clin Respir J. 2021 Oct 31;8(1):1984375.
  36. Fjællegaard K, Petersen JK, Armbruster K, Jensen HK, Skaarup SH, Laursen CB, Clementsen PF, Bødtger U. [Malignant pleural effusion]. Ugeskr Laeger. 2021 Apr 26;183(17):V10200751. In Danish.
  37. Andersen MB, Bodtger U, Andersen IR, Thorup KS, Ganeshan B, Rasmussen F. Metastases or benign adrenal lesions in patients with histopathological verification of lung cancer: Can CT texture analysis distinguish? Eur J Radiol. 2021 May;138:109664.
  38. Clementsen PF, Bodtger U, Konge L, Christiansen IS, Nessar R, Salih GN, Kolekar S, Meyer CN, Colella S, Jenssen C, Herth F, Hocke M, Dietrich CF. Diagnosis and staging of lung cancer with the use of one single echoendoscope in both the trachea and the esophagus: A practical guide. Endosc Ultrasound. 2021 Sep-Oct; 10(5): 325-334.
  39. Christiansen IS, Svendsen MBS, Bodtger U, Sidhu JS, Nessar R, Salih GN, Høegholm A, Clementsen PF. Characterization of Lung Tumors that the Pulmonologist can Biopsy from the Esophagus with Endosonography (EUS-B-FNA). 2021;100(2):135-144.
  40. Ulhoi MP, Sorensen BS, Meldgaard P. Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLCCase Rep Oncol. 2021 Sep 16;14(3):1323-1327
  41. Clement MS, Ebert EBF, Meldgaard P, Sorensen BS. Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. Clin Lung Cancer. 2021 Nov;22(6):e870-e877.
  42. Raaby Gammelgaard K, Sandfeld-Paulsen B, Godsk SH, Demuth C, Meldgaard P, Sorensen BS, Jakobsen MR. cGAS-STING pathway expression as a prognostic tool in NSCLC. Transl Lung Cancer Res. 2021 Jan;10(1):340-354.
  43. Ørum M, Eriksen SV, Gregersen M, Jensen AR, Jensen K, Meldgaard P, Nordsmark M, Damsgaard EM. The impact of a tailored follow-up intervention on comprehensive geriatric assessment in older patients with cancer – a randomised controlled trial. J Geriatr Oncol. 2021 Jan;12(1):41-48.
  44. Månsson CT, Vad-Nielsen J, Meldgaard P, Nielsen AL, Sorensen BS. EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP). Mol Oncol. 2021 Nov;15(11):2868-2876.
  45. Jakobsen AK, Yuusufi S, Madsen LB, Meldgaard P, Knudsen BR, Stougaard M. TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer. 2021 Dec 22;164:23-32.
  46. Jakobsen E, Olsen KE, Bliddal M, Hornbak M, Persson GF, Green A. Forecasting lung cancer incidence, mortality, and prevalence to year 2030. BMC Cancer. 2021 Sep 3;21(1):985.
  47. Szejniuk WM, Cekala M, Bøgsted M, Meristoudis C, McCulloch T, Falkmer UG, Røe OD. Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay. Cancer Treat Res Commun. 2021;27:100318.
  48. Szejniuk WM, Nielsen MS, Takács-Szabó Z, Pawlowski J, Al-Saadi SS, Maidas P, Bøgsted M, McCulloch T, Frøkjær JB, Falkmer UG, Røe OD. High-dose thoracic radiation therapy for non-small cell lung cancer: a novel grading scale of radiation-induced lung injury for symptomatic radiation pneumonitis. Radiat Oncol. 2021 Jul 15;16(1):131.
  49. Pedersen S, Hansen JB, Maltesen RG, Szejniuk WM, Andreassen T, Falkmer U, Kristensen SR. Identifying metabolic alterations in newly diagnosed small cell lung cancer patients.Metabol Open. 2021 Sep 16; 12:100127
  50. Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med. 2021 May 31;19(1):232.
  51. Venkadesh KV, Setio AAA, Schreuder A, Scholten ET, Chung K, W Wille MM, Saghir Z, van Ginneken B, Prokop M, Jacobs C. Deep Learning for Malignancy Risk Estimation of Pulmonary Nodules Detected at Low-Dose Screening CT. 2021 Aug;300(2):438-447.
  52. Bjørnhart B, Hansen KH, Jørgensen TL, Herrstedt J, Schytte T. Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition. Thrombosis Update, Volume 4, 2021, 100056, ISSN 2666-5727
  53. Hoffmann L, Knap MM, Alber M, Møller DS. Optimal beam angle selection and knowledge-based planning significantly reduces radiotherapy dose to organs at risk for lung cancer patients. Acta Oncol. 2021 Mar;60(3):293-299.
  54. Khalil AA, Knap MM, Møller DS, Nyeng TB, Kjeldsen R, Hoffmann L. Local control after stereotactic body radiotherapy of centrally located lung tumours. Acta Oncol. 2021 Aug;60(8):1069-1073
  55. Winther L, Larsen K, Langer SW, Quist M. The 6-Minute Walk Test As A Pre-Treatment Predictor For Adverse Events In Patients With Lung Cancer: A Feasibility Study. J Cancer Rehabil 2021; 4: 91-96
  56. Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Frary JMC, Drivsholm LB, Vesteghem C, Christensen HS, Bjørnhart B, Pøhl M. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy. Cancers (Basel). 2021 Sep 28;13(19):4846. doi: 10.3390/cancers13194846. PMID: 34638329; PMCID: PMC8507718
  57. Dansk Lunge Cancer Register (DLCR) – Resumé af Årsrapport 2019-2020. Ugeskrift Læger


  1. Christensen NL, Rasmussen TR, Hansen KH, Christensen J, Dalton SO. Comorbidity and early death in Danish stage I lung cancer patients – an individualised approach. Acta Oncol. 2020 Aug;59(8):994-1001. doi: 10.1080/0284186X.2020.1764096. Epub 2020 May 28. PMID: 3246334
  2. Skougaard K, Østrup O, Guldbrandsen K, Sørensen B, Meldgaard P, Saghir Z, Gørtz P, Lonsdale MN, Frank MS, Gerke O, Rychwicka-Kielek BA, Persson G, Land LH, Schytte T, Bodtger U, Skuladottir H, Søgaard J, Nielsen SS, Rasmussen TR, Fischer BM. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER). Clin Lung Cancer. 2020 Mar;21(2):e61-e64. doi: 10.1016/j.cllc.2019.11.002. Epub 2019 Nov 21. PMID: 31839533
  3. Christensen J, Jakobsen E. et al: Agreement between The Danish Cancer Registry and The Danish Lung Cancer Registry. Dan Med J 2020;67(8):A04190257


  1. Dansk Lunge Cancer Register (DLCR) – Resumé af Årsrapport 2018. Ugeskrift Læger 182/1
  2. Brønserud M.M, Iachina M, et al.: Patient-reported outcomes (PROs) in lung cancer: Excperiences from a nationwide feasibility study. Lung Cancer 128 (2019) 67-73
  3. Brønserud M.M, Iachina M, et al.: Patient reported outcome data as performance indicators in surgically treated lung cancer patients. Lung Cancer 130 (2019) 143-148
  4. Christensen N.L, Dalton S, et al.: Treatment, no treatment and early death in Danish stage I lung cancer patients. Lung Cancer 131 (2019) 1-5
  5. Rich A., Baldwin D, et al.: Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries, BMC Cancer (2019) 18:114


  1. Jeppesen SS, Hansen NCG et al.: Survival of localized NSCLC patients without active treatment or treated with SBRT. Acta Oncologica 2018 Feb;57(2):219-225
  2. Rich A.L, Baldwin D.R, et al.: ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe. European Respiratory Journal 2018
  3. Møller, H, Goupland V.H, et al.: Geographical variations in the use og cancer treatments are associated with survival of lung cancer patients. Thorax 2018;0:1-8 
  4. Christensen N.L, Kejs A.M.T. et al.: Early death in Danish stage I lung cancer patients: a population-based case study. Acta Oncologica 2018 vol. 57:1561-1566


  1. Guldbrandt LM, Møller H, et al: General practice consultations, diagnostic investigations and prescriptions in the year preceding a lung cancer diagnosis. Cancer Medicine 2017; 6(1):79–88
  2. Eckardt J, Jakobsen E, et al: Subcarinal Lymph Node Schould be Dissection in All Lobectomies for Non-Small Cell Lung Cancer – Regardless of Primary Tumor Location Ann Thorac Surg 2017;103:1121–5
  3. Iachina M., Brønserud MM, et al.: History of Depression in Lung Cancer Patients: Impact of delay. Clinical Oncology 2017 Sep;29(9):585-592
  4. Iachina M, Green A, et al.: Transfer between hospitals as a predictor of delay in diagnosis and treatment of patients with Non-Small Cell Lung Cancer – a register based cohort-study. BMC Health Services Research 2017 Apr 12;17(1):267


  1. Jakobsen E., Rasmussen T.R.: The Danish Lung Cancer Registry. Clinical Epidemiology 2016:8 537-541
  2. Møller H., Jakobsen E et al: High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of readmission and death: national cohort analysis in England. Eur J Cancer. 2016 Sep;64:32-43
  3. Jakobsen E., Rasmussen T.R.: The Danish Lung Cancer Registry. Clinical Epidemiology (2016) publicated online
  4. Jakobsen E., Riis Rasmussen T. et al: Mortality and survival of Lung Cancer in Denmark: Results from the Danish Lung Cancer Group 2002-2012. Acta Oncologica (2016) 1-8
  5. O´Dowd EL, Lüchteenborg M et al: Predicting death from surgery for lung cancer. A comparison of two scoring systems in two European countries. Lung Cancer (2016)95, 88-93
  6. Møller H., Riaz SP et al: High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of readmission and death: national cohort analysis in England. Accepted for publication in European Journal of Cancer


  1. Iachina M., Jakobsen E. et al: The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients. Lung 2015 193:291–297
  2. Laursen LØ, Petersen RH et al: Video-assisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy. Eur J Cardiothoracic Surg (2015); 49(3):870-5
  3. Dalton S, Steding-Jessen M et al.: Socioeconomic position and survival after lung cancer – the influence of stage, treatment and comorbidity among Danish lung cancer patients diagnosed 2004-2010. Acta Oncol.2015 May;54(5):797-804
  4. Green A., Hauge J. et al: The mortality after surgery in primary lung cancer: results from the Danish Lung Cancer Registry. European Journal of Cardio-Thoracic Surgery (2015); 49(2): 589-94
  5. Mellemgaard A., Lüchtenborg M. et al: Role of comorbidity on survival after radio- and chemotherapy for non-surgically treated lung cancer. J Thorac Oncol. 2015 Feb;10(2):272-9


  1. Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions.: The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2014 Nov;9(11):1618-24
  2. Iachina M., Green A., Jakobsen E. et al.: The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariates. BMJ Open 2014;4:e003846
  3. Blum T., Jakobsen E. et al: ERS task force report: The European Initiative for Quality Management in Lung Cancer Care. The European Respiratory Journal 2014/03
  4. Licht P., Schytte T., Jakobsen E.: Adjuvant Chemotherapy Compliance  Is Not superior After Thoracoscopic Lobectomy. Ann Thorac Surg. 2014 Aug;98(2):411-5; discussion 415-6


  1. Lüchtenborg M. et al: Survival of small cell lung cancer patients undergoing lung resection in England 1998- 2009. BMJ  2013
  2. Søgaard R., Fischer BM., Mortensen J., Rasmussen TR., Lassen U.: The Optimality of Different Strategies for Supplemental Staging of Non–Small-Cell Lung Cancer: A Health Economic Decision Analysis. Value in Health 16 (2013): 57-65
  3. Lüchtenborg M., Jakobsen E., Peake M.D., Møller H.: Mortality after surgery for Small Cell Lung Cancer. Thorax 2013;0:1–5
  4. Starr L. et al.: Socioeconomic position and surgery for early-stage non small cell lung cancer: a population-based study in Denmark. Lung Cancer 79 (2013) 262– 269
  5. Walters S. et al: Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom: a population-based study, 2004- 2007. Thorax 2013;0:1–14
  6. Licht P.B. et al: A National Study of Nodal Upstaging After Thoracoscopic Versus Open Lobectomy for Clinical Stage-1 Lung Cancer. Afp. in Annals of Thorcic Surgery
  7. Jakobsen E. et al: Nationwide quality improvement in lung cancer care: The Danish Lung Cancer Registry. in Journal of Thoracic Oncology
  8. Lüchtenborg M. et al: High procedure volume is strongly associated with improved survival after lung cancer surgery. Afp. in Journal of Clinical Oncology
  9. Ledderer L. et al: Feasibility of a psychosocial rehabilitation intervention to enhance the involvement of relatives in cancer rehabilitation. Pilot study for a randomized controlled trial. Sfp. in The Patient: Patient–Centered Outcomes Research
  10. Jakobsen E., Green A.: Benchmarking Consortium: Lungekræft 2000 – 2012 
  11. Skov B.G, Høgdal E. et al.: The prevalence of EGFR mutations in non-small cell lung cancer in an unseleted Caucasian population APMS 123: 108-116

2012 og før

  1. Lüchtenborg M. et al: The effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patients. European Journal of Cancer 2012;48(18):3386-95
  2. Jakobsen E. et al: Dansk Lunge Cancer Register. Ugeskr Læger 174/42, 2012; 2539
  3. Wildgaard K, Ravn J, et al.: Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study. Acta Anaesthesiol Scan 2011 55:60-68
  4. Dalton SO, Frederiksen BL et al.: Socioeconomic position, stage of lung cancer and time between referral and diagnosis in Denmark, 2001-2008BJC (2011) 105, 1042-1048
  5. Lipczak H., Neckelmann K. et al.: Uncertain added value of global Trigger Tool for monitoring of patient safety in cancer care. Dan Med Bul 58/11
  6. Jakobsen E, Palshof T. et al.: Data from a national lung cancer registry contributes to improve outcome an quality of surgery: Danish results. Car.thor. sur. 2009, 35 (2): 348-52
  7. Jakobsen E. et al: Nationwide quality improvement in lung cancer care: The Danish Lung Cancer Registry. in Journal of Thoracic Oncology
  8. Lüchtenborg M. et al: High procedure volume is strongly associated with improved survival after lung cancer surgery. in Journal of Clinical Oncology
  9. Ledderer L. et al: Feasibility of a psychosocial rehabilitation intervention to enhance the involvement of relatives in cancer rehabilitation. Pilot study for a randomized controlled trial. in The Patient: Patient–Centered Outcomes Research
  10. Jakobsen E., Green A.:dk Benchmarking Consortium: Lungekræft 2000 – 2012 
  11. Skov B.G, Høgdal E. et al.: The prevalence of EGFR mutations in non-small cell lung cancer in an unseleted Caucasian populationAPMS 123: 108-116
  12. Møller H., Riaz SP et al: High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of readmission and death: national cohort analysis in England. Accepted for publication in European Journal of Cancer